BG-75202 features among several projects starting first-in-human trials.
ApexOnco Front Page
Recent articles
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
And the company might one day follow Galapagos into decentralised manufacturing.
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
In first-line NSCLC the drug beats chemo, and not Keytruda.
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
